Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ARDS
- Sponsor
- Charite University, Berlin, Germany
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Natural killer cells Cells (CD16 pos)
- Status
- Recruiting
- Last Updated
- 3 months ago
Overview
Brief Summary
This is a retrospective observational study over the period 1/2019 - 02/2024 with the aim of identifying patients with a predisposition to secondary infections.
Detailed Description
As a reference center, Charité Universitaetsmedizin Berlin has been treating patients with the most severe form of acute respiratory failure, known as acute respiratory distress syndrome (ARDS), for more than 30 years. Despite lung-protective forms of ventilation and the use of extracorporeal procedures for oxygenation and decarboxylation (ECMO), mortality is around forty percent. In addition to the primary cause of ARDS, further infectious complications often develop during the course of the disease, which delay recovery. The aim of this study is to investigate infectious complications (ventilator-associated pneumonia, reactivation of Herpes viridae, pathogen resistance despite formally correct therapy, fungal infections) depending on the immune status.
Investigators
Claudia Spies
Head of the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK)
Charite University, Berlin, Germany
Eligibility Criteria
Inclusion Criteria
- •Male and female acute respiratory distress syndrome patients who had an immune status within 48 h of admission
- •Patients who received intensive care treatment for acute respiratory distress syndrome ward 8i at Charité in the period from 01/2019 to 02/2024 with a maximum follow-up period of 90 days
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Natural killer cells Cells (CD16 pos)
Time Frame: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes.
HLA-DR expression on monocytes
Time Frame: 01/2019- 02/2024
in molecules per cell
Herpes simplex reactivation
Time Frame: 01/2019- 02/2024
semi-quantitatively with Herpes simplex (negative / slightly positive / positive and strongly positive) in blood or bronchial lavage
B cells (CD19 positive)
Time Frame: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes
Cytomegalovirus reactivation
Time Frame: 01/2019- 02/2024
as absolute copy number per milliliter of blood or bronchioalveolar lavage
Cytotoxic T cells (CD8)
Time Frame: 01/2019- 02/2024
Absolute number per nanoliter and percentage of lymphocytes
Epstein Barr virus reactivation
Time Frame: 01/2019- 02/2024
absolute copy number per milliliter of blood or bronchioalveolar lavage
T helper cells (CD4)
Time Frame: 01/2019- 02/2024
Aabsolute number per nanoliter and percentage of lymphocytes
Secondary Outcomes
- Pathogen persistence after guideline-compliant therapy (yes/no)(01/2019- 02/2024)
- Catecholamine doses(01/2019- 02/2024)
- Number of catecholamine days(01/2019- 02/2024)
- Recording of end organ damage such as liver and kidney failure(01/2019- 02/2024)
- Costs of treatment(01/2019- 02/2024)
- Ventilator-associated pneumonia (yes/no)(01/2019- 02/2024)
- Concomitant infections with therapy(01/2019- 02/2024)
- Volumes(01/2019- 02/2024)
- Diagnoses during the intensive care stay(01/2019- 02/2024)
- Administration of immunosuppressants(01/2019- 02/2024)
- Extracorporeal membrane oxygenation duration(01/2019- 02/2024)
- Occurrence of fungal pneumonia (yes/no)(01/2019- 02/2024)
- Simplified Acute Physiology Score (SAPS II)(01/2019- 02/2024)
- Beginn weaning(01/2019- 02/2024)
- Ventilation parameters(01/2019- 02/2024)
- Mortality(01/2019- 02/2024)
- Sequential Organ Failure Assessment (SOFA score)(01/2019- 02/2024)
- Pre-existing conditions(01/2019- 02/2024)